Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?
NCT ID: NCT04696913
Last Updated: 2021-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
347 participants
OBSERVATIONAL
2021-01-01
2021-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
COVID-19 associated pulmonary arterial microthrombosis and coagulopathy has prompted physicians to implicate pulmonary embolism (PE) as a potential cause for acute respiratory deterioration.
Literature review reveals few studies of varying size, quality and design. Recent meta-analysis reports venous thromboembolism in approximately 20% of COVID-19 patients. There has yet to be a case-controlled study which proves and quantifies the associated between COVID-19 and PE.Confirming and quantifying this association has numerous clinical implications for the treatment of critically unwell patients with COVID-19 infection. For example, clinicians will be more inclined to investigate and treat sudden deteriorations with the knowledge that pulmonary embolism is the commonest cause for said deteriorations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels
NCT04373486
Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms
NCT04420312
Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients.
NCT05353608
Pulmonary Optical Coherence Tomography in COVID-19 Patients
NCT04410549
Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic
NCT04465656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CTPA reports and test results of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for COVID-19 will be reviewed via electronic medical records.
Patients with no COVID-19 RT-PCR test done within 7 days of the CTPA or the same clinical episode will be excluded. Patients who had repeat CTPAs, who are already known to have a PE, and who had CTPAs which are considered to be radiologically inadequate will be excluded.
Patients will be categorised into cases (positive PE) and controls (negative PE).
CTPA images of cases will be reviewed to collect further data about severity, distribution and right heart strain.
Patients' exposure status will also be determined (positive or negative for COVID- 19 infection).
The primary outcome is the number of pulmonary embolism cases related to COVID19.
The secondary outcomes are the severity, distribution of pulmonary embolism as determined by calculated Qanadli score. Presence of right heart strain.
Further data for the multivariate analysis will be obtained from the patient's electronic medical record. Specifically, we will collect data on risk factors for COVID-19 infection and PE to correct for confounding.
Statistical data analysis by various hypothesis tests and multivariate logistic regression will be conducted to determine the odds ratio of developing a PE, given positive COVID-19 infection.
Patients with a positive PE will have their scans reviewed to quantitatively assess their clot burden and degree of right heart strain. The former will be done by calculating a Qanadil score. The latter will be done my measuring the right ventricle- left ventricle ratio. This will allow for a comparison between COVID-19 infected and non-infected patients with PE.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pulmonary Embolism Positive
As determined by CT Pulmonary Angiogram
Exposure: Positive COVID-19 infection
Exposure: Positive COVID-19 infection as determined by RT-PCR
Exposure: Negative COVID-19 infection
Exposure: Negative COVID-19 infection as determined by RT-PCR
Pulmonary Embolism Negative
As determined by CT Pulmonary Angiogram
Exposure: Positive COVID-19 infection
Exposure: Positive COVID-19 infection as determined by RT-PCR
Exposure: Negative COVID-19 infection
Exposure: Negative COVID-19 infection as determined by RT-PCR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure: Positive COVID-19 infection
Exposure: Positive COVID-19 infection as determined by RT-PCR
Exposure: Negative COVID-19 infection
Exposure: Negative COVID-19 infection as determined by RT-PCR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Duplicate CT pulmonary angiograms.
* Patients who are already known to have a pulmonary embolism.
* Patients who had radiologically inadequate CT pulmonary angiograms.
* Patients younger than 16 years old.
* Patients who have incomplete or unavailable notes.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aberdeen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-073-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.